Trial Profile
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Myxoid liposarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms IGNYTE-ESO
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 11 Jul 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 28 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2022 Planned number of patients changed from 80 to 97.